文摘
摘要目的:是否添加寡克隆乐队(时常)状态(现在/脑脊液(CSF)中缺席)改善2005年和2016年提议MAGNIMS MRI的表现标准传播在空间(DIS)预测临床事件符合儿童中枢神经系统脱髓鞘的放射检查孤立综合症(RIS),使用2010定义MRI DIS (RIS - 2010)标准。
背景:改善了RIS的诊断标准预测哪些孩子需要先建立一个临床事件。我们报道,无论是2005还是2016 MAGNIMS MRI说标准都高灵敏度和特异性预测临床事件ris的孩子- 2010。
设计/方法:我们分析了一个历史的儿童与ris(< 18年)——2010年国际纵向研究。我们决定孩子是否还会见了2005年和2016年MAGNIMS MRI说在基线和标准是否≥2 CSF中拥有独特的台籍干部。我们计算敏感性和特异性不同MRI说有或没有标准的台籍干部身份。
结果:55儿童ris - 2010, 33例(60%)有台籍干部地位决定,包括(6米/ 27个f,平均随访= 5.3±5.2年)。19/33的孩子时常测试+(58%)和15/33的孩子(45%)开发了一种临床事件。C.I.诊断指标和95%年代为2005年说标准有无油断路器状态是:灵敏度67%(38% - -88%)和67% (41% - -87%);特异性83%(59% - -96%)和53% (35% - -70%)。2016年MAGNIMS说标准诊断指标是:灵敏度87%(60% - -98%)和100%(82% - -100%)和特异性72%(46% - -90%)和25% (11% - -41%)。
结论:台籍干部的地位提高了2005年和2016年的特异性MAGNIMS MRI标准说预测临床事件ris的孩子- 2010。2016 MAGNIMS说标准+油断路器状态最好的敏感性和特异性的结合。
研究支持:
本研究资助,部分由格兰特K23NS101099从国家神经疾病和中风研究所(研究所)和CTSA目前授予数量UL1 TR000142从国家推进转化科学中心(NCATS)在美国国立卫生研究院NIH医学研究路线图。其内容是完全的责任作者和不一定代表NIH的官方观点。
披露:Makhani博士没有披露。Lebrun-Freney博士已经收到个人赔偿咨询、担任科学顾问委员会说,与咨询费或其他活动,酬金或科学委员会支持:拜耳先灵葆雅,生原体,Genzyme,默克公司Serono,诺华,Teva。湿婆博士已经收到个人赔偿咨询、担任科学顾问委员会说,与默克公司或其他活动,诺华,Teva, Genzyme,拜耳,罗氏。Narula博士没有披露。沃斯默博士没有披露。Brenton博士没有披露。Brassat博士已经收到个人赔偿咨询、担任科学顾问委员会说,与拜耳或其他活动,生原体,MedDay,默克公司Serono,诺华,Sanofi-Genzyme,罗氏,Teva。Carra-Dalliere博士没有披露。博士德Seze已收到个人赔偿咨询、担任科学顾问委员会说,与赛诺菲安万特或其他活动。De Seze博士接受了赛诺菲的研究支持。 Dr. Durand Dubief has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Sanofi-Genzyme, Novartis, Teva, Merck, Roche. Dr. Langille has nothing to disclose. Dr. Neuteboom has nothing to disclose. Dr. Pelletier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Sanofi-Genzyme, Novartis, Teva, Merck-Serono, Roche, MedDay. Dr. Pelletier has received research support from Biogen, Novartis, Roche, Merck-Serono. Dr. Pohl has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Forward. Dr. Reich has nothing to disclose. Dr. Rojas has nothing to disclose. Dr. Shabanova has nothing to disclose. Dr. Shapiro has nothing to disclose. Dr. Thompson-Stone has nothing to disclose. Dr. Tenembaum has nothing to disclose. Dr. Tintoré has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer Schering Pharma, Merck-Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, Novartis, Almirall, Genzyme, and Roche. Dr. Uygunoglu has nothing to disclose. Dr. Vargas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion Pharmaceuticals. Dr. Vargas has received research support from Teva Pharmaceuticals. Dr. Venkateswaran has nothing to disclose. Dr. Kantarci has nothing to disclose. Dr. Okuda has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, EMD Serono, Genentech, Genzyme, Novartis, and Teva. Dr. Pelletier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. Pelletier has received research support from Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. (OFSEP) has nothing to disclose. Dr. (SFSEP) has nothing to disclose. Dr. (RISC) has nothing to disclose. Dr. Consortium (PARIS) has nothing to disclose.
